Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial

BMJ Open
Jennifer LeweyNiteesh K Choudhry

Abstract

Adherence to and persistence of medications for chronic diseases remains poor and many interventions to improve medication use have only been modestly effective. Targeting interventions to patients who are most likely to benefit should improve their efficiency and clinical impact. This study aims to test the impact of three cost-equivalent pharmacist-led interventions on insulin persistence and glycaemic control among patients with diabetes. TARGIT-Diabetes (Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes) is a randomised controlled trial that will evaluate three different multifaceted pharmacist-outreach strategies for improving long-term insulin use among individuals with diabetes. We will randomise 6000 patients in a large insurer to one of three arms. The arms are designed to deliver an increasingly intensive intervention to a progressively targeted population, identified using predictive analytics. The central component of the intervention in all arms is a tailored telephone consultation with a pharmacist which varies across arms based on the: (A) proportion of patients offered the intervention and (B) intervention intensity, including follow-up frequency and cointe...Continue Reading

Associated Clinical Trials

Jul 27, 2016·Niteesh K. Choudhry, MD, PhDNiteesh K. Choudhry, MD, PhD

Citations

May 26, 2018·Current Diabetes Reports·Marie E McDonnell
Aug 1, 2021·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Tetsuya YamamotoRyoichi Ishibashi

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02846779

Software Mentioned

TARGIT
Mobile Commons
Horizon
Diabetes
RxAnte

Related Concepts

Related Feeds

Biomarkers for Type 2 Diabetes

Biomarkers can help understand chronic diseases and assist in risk prediction for prevention and early detection of diseases. Here is the latest research on biomarkers in type 2 diabetes, a disease in which the body is unable to produce or properly use insulin.